Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 31

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 31
---
 £0.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each, which
became effective on November 25, 2024.

On January 17, 2025, we entered into the an equity line of credit agreement, or ELOC, with the Selling Stockholder pursuant to which we, subject to the restrictions and satisfaction of the conditions in the ELOC, have the right, but not the obligation, to sell tothe
Selling Stockholder, andthe Selling Stockholder is obligated to purchase, up to $35.0 million of newly issued Depositary Shares over a 36-month period, unless the ELOC is terminated in accordance with its terms. As of the date of this prospectus, we have sold 17,398,000,000 Ordinary Shares under the ELOC, for gross proceeds of approximately $4.9 million, andissued 1,533,490,000 Ordinary Shares to the Selling Stockholder in satisfaction of a commitment
fee.

| 23 |

Options

We have established the Biodexa
Pharmaceuticals PLC Enterprise Management Incentive and Unapproved Option Scheme to allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December 2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved stock options by the Company. As of December 31, 2024, there were options to purchase328,823,388 Ordinary Shares. The options
lapse after ten years from the date of the grant. As of December 31, 2024, the weighted average remaining life of the options was 9.0
years.

In connection with our acquisition
of DARA Biosciences, Inc., or DARA, in December 2015, we assumed all of DARA’s outstanding options, or DARA Options. As of December
31, 2024 there were outstanding DARA Options to purchase 99 Ordinary Shares with a weighted average remaining life of 0.2 years.

Warrants

October 2019 and May 2020 Warrants

In October 2019, we completed
a private placement with certain institutional investors, or the October Private Placement, where we issued warrants to certain investors,
or the October